Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging

Monga, Manju; Carmichael, John A.; Shelley, Wendy; Kirk, Mary Ellen; Krepart, Garry V.; Jeffrey, John; Pater, Joseph L.

doi:10.1016/0090-8258(91)90018-z

Cited by 46 publications

(17 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Two recent large randomized prospective trials showed an 82% 5-year overall and 76% 5-year disease-free survival for patients with early-stage disease treated with surgery followed by platinum-based chemotherapy. 3 Given the excellent outcomes seen in many studies for women with early-stage invasive epithelial ovarian cancer, issues related to quality of life become important for survivors.…”

mentioning

confidence: 99%

Long-Term Survival After Fertility-Sparing Surgery for Epithelial Ovarian Cancer

Schlaerth

Dennis

Poynor

et al. 2009

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Long-Term Survival After Fertility-Sparing Surgery for Epithelial Ovarian Cancer

Schlaerth

Dennis

Poynor

et al. 2009

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…On the other hand, most studies have demonstrated that response to neoadjuvant chemotherapy (NACT) in primarily unresectable ovarian cancer patients allows cytoreduction to be achieved in 67–84% of the cases, resulting in a longer time to progression (TTP) and overall survival (OS) than in unresponsive patients not eligible for interval debulking surgery (IDS) [8, 9, 10, 11]. Some studies indicate that patients who have undergone optimal cytoreduction after induction therapy have approximately the same outcome as patients optimally cytoreduced during primary surgery [12, 13]. These data, however, have not been confirmed by other authors [14, 15].…”

Section: Introductionmentioning

confidence: 99%

Impact of Interval Debulking Surgery on Clinical Outcome in Primary Unresectable FIGO Stage IIIc Ovarian Cancer Patients

Fanfani

Ferrandina

Corrado³

et al. 2003

Oncology

View full text Add to dashboard Cite

Objectives: To report the results of neoadjuvant chemotherapy (NACT) and the impact of interval debulking surgery (IDS) on clinical outcomes of patients considered unresectable at primary surgery. Methods: Retrospective analysis was carried out on 73 consecutive stage IIIc ovarian cancer patients treated with platinum-based NACT followed by IDS. Their clinical outcomes were compared with those of 111 consecutive stage IIIc ovarian cancer patients treated with primary cytoreduction followed by platinum-based adjuvant chemotherapy. Results: Patients who underwent successful IDS had a more favorable prognosis than those who did not in terms of time to progression (TTP) (p = 0.00001), and overall survival (OS) (p = 0.0001). On the other hand, in the group of patients that underwent successful IDS, no differences in survival outcomes were observed between patients with no residual disease and patients with macroscopic residual disease <2 cm after IDS (p = n.s.). Conclusions: NACT followed by successful IDS can achieve good results in terms of survival outcomes in a high percentage of chemoresponsive IIIc ovarian cancer patients classified as unresectable at primary surgery. These results are in fact inferior to those achievable with optimal primary cytoreduction; however, they were quite similar to those seen with suboptimal primary cytoreduction.

show abstract

“…In the early stages of EOC, it is essential to accurately predict each patient's prognosis and select appropriate [6] suggested that women with low-risk cancers, defined as stage IA or IB, grade 1 or 2, or non-clear-cell histology, do not need further adjuvant therapy, and the currently used clinical therapeutic strategies are based on this approach [7,8]. Moreover, the clinical implications of EOC grades are widely accepted with respect to non-clear-cell histology [9][10][11].…”

Section: Discussionmentioning

confidence: 99%

Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma

Matsumoto

Umezawa

Sasaki

et al. 2011

Pathol. Oncol. Res.

View full text Add to dashboard Cite

In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7-124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9-768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.

show abstract

Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging

Cited by 46 publications

References 1 publication

Long-Term Survival After Fertility-Sparing Surgery for Epithelial Ovarian Cancer

Long-Term Survival After Fertility-Sparing Surgery for Epithelial Ovarian Cancer

Impact of Interval Debulking Surgery on Clinical Outcome in Primary Unresectable FIGO Stage IIIc Ovarian Cancer Patients

Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma

Contact Info

Product

Resources

About